Mainstream

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Post Contentnvo, lly, ivbiy, ivbxfRead More

You might also be interested in reading XRP To Triple Digits? Analyst Confident In $100 Price Goal.

June 30, 2025
In Mainstream